FDA Issues Public Health Advisory Related to Risks Associated With Kratom – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Food and Drug Administration (FDA) issued a public health advisory related to increasing concerns about the risks associated with the use of kratom, a plant that grows naturally in Thailand, Malaysia, Indonesia, and Papua New Guinea. The agency is concerned that kratom, which affects the same opioid brain receptors as morphine, appears to have properties that expose users to the risks of addiction, abuse, and dependence. FDA warns consumers to not use any products labeled as containing kratom or its psychoactive compounds, such as mitragynine and 7-hydroxymitragynine. Although there are no FDA-approved uses for kratom, the agency knows people are using kratom to treat conditions like pain, anxiety, and depression, and that this substance is being actively marketed and distributed for these purposes, indicates FDA Commissioner Scott Gottlieb, MD, in a statement.
FDA has taken action against kratom-containing dietary supplements. The agency identified kratom products on two import alerts, and is working to prevent shipments of kratom from entering the US. Additionally, FDA has detained hundreds of shipments of kratom at international mail facilities. The agency also used its authority to conduct seizures and to oversee the voluntary destruction of kratom products.